20
Samsung Biologics
207940.KS·KRXIncheon KRFounded 20117,000 employees
Large CapbiotechPublicOncology
Platform: CDMO
Market Cap
$40B
All Drugs
9
Clinical Trials
21
Failed / Terminated
5
FDA Approved
2
Stock Price & Catalysts (207940.KS)
Loading 207940.KS stock data...
Drug Pipeline (9 programs)
| Drug Name | Code | Phase | Trials | Modality | Target | MOA | Indications |
|---|---|---|---|---|---|---|---|
| 207-5197 | 207-5197 | Approved | 4 | BET | SchizophreniaET | ||
| Talatuximab | 207-8449 | Preclinical | 1 | CD3 | Bladder CaGA | ||
| Sematenlimab | 207-5236 | Phase 3 | 4 | PI3Kα | DLBCLT2D | ||
| Rilufotisoran | 207-9090 | NDA/BLA | 1 | FXIa | HCC | ||
| 207-2754 | 207-2754 | Phase 1/2 | 2 | KRASG12D | Heart FailureGBM | ||
| Gelisertib | 207-6888 | Approved | 3 | IL-23 | PsoriasisRA | ||
| Geliglumide | 207-1462 | Phase 1 | 2 | Aβ | OCDACC | ||
| Doxasotorasib | 207-4710 | Phase 2/3 | 2 | CFTR | AngelmanALL | ||
| Talatapinarof | 207-2662 | Phase 1/2 | 2 | PCSK9 | MelanomaFSGS |
SEC Filings & Financial Documents
SEC filings are not available for KRX-listed companies.
Samsung Biologics trades on KRX (KR). SEC EDGAR only covers US-listed issuers.
Insider Trading Activity
Insider trading data is not available for non-US exchanges.
Catalyst Events (21)